Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David Erwin Kleiner, Elizabeth M. Brunt, Mark L. Van Natta, Cynthia A. Behling, Melissa J. Contos, Oscar W. Cummings, Linda D. Ferrell, Yao‐Chang Liu, Michael S Torbenson, Aynur Ünalp–Arida, Matthew M. Yeh, Arthur J. McCullough, Arun Jayant Sanyal
Hepatology · 2005 · 10,957 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Kleiner, D. E., Brunt, E. M., Natta, M. L. V., Behling, C. A., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Ünalp–Arida, A., Yeh, M. M., McCullough, A. J., & Sanyal, A. J. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease†. Hepatology, 41(6), 1313–1321. https://doi.org/10.1002/hep.20701
In text: (Kleiner et al., 2005)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
Related papers
- Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test2004
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis1996
- Nonalcoholic Fatty Liver Disease2002
- Liver fibrosis2005
- Wound Healing--Aiming for Perfect Skin Regeneration1997
Metadata from OpenAlex (CC0). Citations are generated from the published record.